Restaurant company Bloomin’ Brands (NASDAQ:BLMN) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 18.6% year on year to $972 million. Its non-GAAP profit of $0.22 per share was 39.7% below analysts’ consensus estimates.
Industrials businesses quietly power the physical things we depend on, from cars and homes to e-commerce infrastructure. Still, their generally high capital requirements expose them to the ups and downs of economic cycles, and the market seems confused about where we could go next. This uncertainty has led to a flat return for the industry over the past six months while the S&P 500 was up 6.4%.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.5% year on year to $391.1 million. On the other hand, the company’s full-year revenue guidance of $1.58 billion at the midpoint came in 2.3% below analysts’ estimates. Its non-GAAP profit of $1.59 per share was 3% above analysts’ consensus estimates.
Retailers are overhauling their operations as technology redefines the shopping experience. Still, secular trends are working against their favor as e-commerce continues to take share from brick and mortars. This puts retail stocks in a tough spot, and over the past six months, the industry has pulled back by 3.7%. This performance is a stark contrast from the S&P 500’s 6.4% gain.
Coconut water company The Vita Coco Company (NASDAQ:COCO) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 19.9% year on year to $127.3 million. On the other hand, the company’s full-year revenue guidance of $562.5 million at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.06 per share was in line with analysts’ consensus estimates.
Infrastructure design software provider Bentley Systems (NASDAQ:BSY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 12.6% year on year to $349.8 million. On the other hand, the company’s full-year revenue guidance of $1.48 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.21 per share was in line with analysts’ consensus estimates.
Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was 1.2% below analysts’ consensus estimates.
Beverage company Zevia (NYSE:ZVIA) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.4% year on year to $39.46 million. On the other hand, next quarter’s revenue guidance of $37 million was less impressive, coming in 10.1% below analysts’ estimates. Its GAAP loss of $0.09 per share was 15.4% below analysts’ consensus estimates.
News of the day for Feb. 26, 2025
Shoe and apparel company Steven Madden (NASDAQ:SHOO) announced better-than-expected revenue in Q4 CY2024, with sales up 12% year on year to $582.3 million. Its GAAP profit of $0.49 per share was 8.7% below analysts’ consensus estimates.